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Astrocyte reactivity is a hallmark of neurodegenerative diseases (ND), but its effects on disease outcomes remain highly debated.
Elucidation of the signaling cascades inducing reactivity in astrocytes during ND would help characterize the function of these cells and
identify novel molecular targets to modulate disease progression. The Janus kinase/signal transducer and activator of transcription 3
(JAK/STAT3) pathway is associated with reactive astrocytes inmodels of acute injury, but it is unknownwhether this pathway is directly
responsible for astrocyte reactivity inprogressivepathological conditions suchasND. In this study,we examinedwhether the JAK/STAT3
pathway promotes astrocyte reactivity in several animal models of ND. The JAK/STAT3 pathway was activated in reactive astrocytes in
two transgenicmousemodels of Alzheimer’s disease and in amouse and a nonhuman primate lentiviral vector-basedmodel of Hunting-
ton’s disease (HD). To determine whether this cascade was instrumental for astrocyte reactivity, we used a lentiviral vector that specifi-
cally targets astrocytes in vivo to overexpress the endogenous inhibitor of the JAK/STAT3 pathway [suppressor of cytokine signaling 3
(SOCS3)]. SOCS3 significantly inhibited this pathway in astrocytes, prevented astrocyte reactivity, and decreasedmicroglial activation in
models of both diseases. Inhibition of the JAK/STAT3 pathway within reactive astrocytes also increased the number of huntingtin
aggregates, a neuropathological hallmark of HD, but did not influence neuronal death. Our data demonstrate that the JAK/STAT3
pathway is a common mediator of astrocyte reactivity that is highly conserved between disease states, species, and brain regions. This
universal signaling cascade represents a potent target to study the role of reactive astrocytes in ND.
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Introduction
In response to multiple pathological conditions, astrocytes
undergo molecular, morphological, and functional changes,
referred to as astrocyte reactivity (Sofroniew and Vinters,
2010). They become hypertrophic, upregulate intermediate
filament proteins, including GFAP and vimentin, and display
functional alterations that are still not fully understood.
Astrocyte reactivity occurs in both acute and progressive path-
ological conditions and is a hallmark of multiple neurodegen-
erative diseases (ND; Sofroniew and Vinters, 2010). Astrocyte
reactivity develops in vulnerable regions at the early stages of
ND and progresses along with neurological symptoms and cell
death. Reactive astrocytes are observed in close proximity to
amyloid depositions in both patients with Alzheimer’s disease
(AD) and mouse models of AD (Probst et al., 1982; Itagaki et
al., 1989). They are also found in the striatum and cortex of
patients with Huntington’s disease (HD) and some mouse
models of HD (Vonsattel et al., 1985; Yu et al., 2003; Faideau et
al., 2010).
The involvement of reactive astrocytes in disease progres-
sion is highly controversial. Although they are generally con-
sidered as detrimental for neuronal function, several studies
suggest that reactive astrocytes may have beneficial effects and
promote neuronal survival (Escartin and Bonvento, 2008;
Hamby and Sofroniew, 2010). In any case, elucidation of the
precise molecular cascades that lead to astrocyte reactivity
may help identify potential therapeutic targets to modulate
disease progression.
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Astrocytes can sense many extracellular signals, such as cyto-
kines, growth factors, nucleotides, endothelins, or ephrins, that
activate various intracellular signaling pathways, such as the
mitogen-activated protein kinase, the nuclear factorB (NF-B),
and the Janus kinase/signal transducer and activator of transcrip-
tion (JAK/STAT) pathways (Kang and He´bert, 2011). Among
them, the JAK/STAT3 pathway appears as a central player in the
induction of astrocyte reactivity. It is activated by a variety of
cytokines and growth factors that signal through the gp130 recep-
tor (Levy and Darnell, 2002). Activation of the JAK/STAT3 path-
way has been observed in reactive astrocytes in several conditions
of acute injury (Justicia et al., 2000; Okada et al., 2006; Herrmann
et al., 2008; O’Callaghan et al., 2014) and in patients and mouse
models of amyotrophic lateral sclerosis (ALS; Shibata et al., 2009,
2010). However, it remains to be demonstrated whether the JAK/
STAT3 pathway is directly responsible for astrocyte reactivity
during progressive pathological conditions such as ND.
In this study, we show that the JAK/STAT3 pathway is acti-
vated in reactive astrocytes in several mouse and nonhuman pri-
mate models of AD and HD. Overexpression of suppressor of
cytokine signaling 3 (SOCS3), the endogenous inhibitor of the
JAK/STAT3 pathway in astrocytes in vivo, inhibited this pathway
and prevented astrocyte reactivity. It also reducedmicroglial activa-
tion and increased the formation ofmutant huntingtin (Htt) aggre-
gates but did not affect neuronal death. These results identify the
JAK/STAT3 pathway as a universal inducer of astrocyte reactivity,
and its modulation affects several pathological features in ND.
Materials andMethods
Transgenic mouse models. Amyloid precursor protein (APP)/Presenilin 1
(PS1) mice [B6.Cg-Tg (APPswe, PSEN1dE9) 85Dbo (http://jaxmice.jax.
org/strain/005864.html)] harbor the chimeric mouse/human APP gene
with Swedish mutations K594N and M595L (APPswe) and the human
PS1 variant lacking exon 9 on a C57BL/6J (http://jaxmice.jax.org/
strain/000664.html) background (Jankowsky et al., 2004). APP/PS1dE9
breeding pairs were obtained fromThe Jackson Laboratory. Triple trans-
genic AD (3xTg-AD) mice express the mutated human APPswe,
PS1M146V, and tauP301L transgenes on a mixed 129Sv (http://jaxmice.
jax.org/strain/002448.html) and C57BL/6J background (Oddo et al.,
2003). Breeding pairs of 3xTg-AD mice were obtained from the Mutant
Mouse Regional Resource Centers. We used 8-month-old APP/PS1dE9
heterozygous females, 12-month-old 3xTg-AD homozygous females,
and their respective age-matched wild-type (WT) control mice. Geno-
typing by PCRwas performed at 4–6weeks of age for APP/PS1dE9mice.
All experimental procedures were approved by a local ethics committee
and submitted to the French Ministry of Education and Research (Ap-
proval 10-057). They were performed in strict accordance with the rec-
ommendations of the European Union (86/609/EEC) for the care and
use of laboratory animals.
Lentiviral vectors and injections in mice.We used self-inactivated lenti-
viral vectors containing the central polypurine tract sequence, themouse
phosphoglycerate kinase I promoter, and the woodchuck postregulatory
element sequence. We used two types of vectors to mediate transgene
expression in either neurons or astrocytes. To target neurons, lentiviral
vectors were pseudotyped with the G-protein of the vesicular stomatitis
virus (Naldini et al., 1996). To target astrocytes, lentiviral vectors were
pseudotyped with the G-protein of the Mokola lyssaviruses and con-
tained four copies of the target sequence of the neuronal miRNA124 to
repress transgene expression in neurons (Colin et al., 2009). Lentiviral
vectors are referred to as “lenti-name of the transgene” in the subsequent
sections of this manuscript. Neuron-targeted vectors encoded the first
171 N-terminal amino acids of human Htt cDNA with either 18 (lenti-
Htt18Q) or 82 (lenti-Htt82Q) polyglutamine repeats (de Almeida et al.,
2002). Astrocyte-targeted vectors encoded either the enhanced green flu-
orescent protein cDNA (lenti-GFP) or the murine SOCS3 cDNA (lenti-
SOCS3; Bjørbaek et al., 1998).
The production and titration of these lentiviruses have been described
previously (Hottinger et al., 2000). Lentiviral vectors were diluted in 0.1
M PBS with 1% BSA at a final concentration of 100 ng p24/l. Mice were
anesthetized with a mixture of ketamine (150 mg/kg) and xylazine (10
mg/kg). Lidocaine (5 mg/kg) was injected subcutaneously under the
scalp 5 min before the beginning of surgery. C57BL/6J and 3xTg-AD
mice received bilateral stereotaxic injections of diluted lentiviral vectors
in the striatum or the subiculum, respectively, administered by a 10 l
Hamilton syringe via a 34 gauge blunt needle. The stereotaxic coordi-
nates used were as follows: for the striatum, anteroposterior (AP), 1
mm; lateral (L), 2 mm from bregma; ventral (V), 2.5 mm from the
dura; and for the subiculum, AP,2.92 mm; L,1.5 mm; V,1.5 mm,
with ear bars set at 4mmand a tooth bar set at 0mm.Mice received a total
volume of 2.5 or 3.5 l per injection site at a rate of 0.25 l/min. At the
end of the injection, the needle was left in place for 5 min before being
removed slowly. The skin was sutured, andmice were allowed to recover.
For the lentiviral vector-based HD model (de Almeida et al., 2002),
8-week-oldmale C57BL/6Jmicewere injectedwith lenti-Htt18Q (100 ng
of p24) and lenti-GFP (150 ng of p24) in the left striatum and with
lenti-Htt82Q (100 ng of p24) and lenti-GFP (150 ng of p24) in the right
striatum.
To inhibit the JAK/STAT3pathway in theHDmodel, 8-week-oldmale
C57BL/6mice were injected bilaterally in the striatumwith lenti-Htt82Q
(150 ng of p24) and coinjectedwith the control lenti-GFP (200 ng of p24)
in the left striatum and with lenti-SOCS3 (150 ng of p24) and lenti-GFP
(50 ng of p24) in the right striatum. To inhibit the JAK/STAT3 pathway
in the ADmodel, 7- to 8-month-old 3xTg-AD female mice were injected
in the subiculum with either lenti-GFP (250 ng of p24) or lenti-SOCS3
(200 ng of p24) and lenti-GFP (50 ng of p24). Coinjections with lenti-
GFPwere performed to visualize the infected area and themorphology of
infected cells as SOCS3 cannot be detected by immunohistochemistry
because of the lack of specific antibodies. Postmortem analysis was per-
formed 6 weeks after injection for HD mice and 4.5 months after injec-
tion for 3xTg-AD mice.
Primatemodel of HD.Three adultmale cynomolgusmonkeys (Macaca
fascicularis, 4.2 0.08 kg) were used in this study according to European
(European Union Directive 86/609/EEC) and French (French Act Rural
Code R 214-87-131) regulations. The animal facility was approved by
veterinarian inspectors (Authorization 92-032-02) and complies with
Standards forHumane Care andUse of Laboratory Animals of theOffice
of Laboratory Animal Welfare (A5826-01).
Magnetic resonance imaging (MRI) was performed on each macaque
to calculate stereotaxic coordinates for lentiviral injection. MRI was per-
formed on a 7 Tesla scanner (Varian) with the following parameters: TR,
15 ms; TE, 5500 ms; TI, 10 ms; flip angle, 90°; and 0.45 0.45 1 mm
with coronal acquisition on a 256  256  40 matrix. For lentiviral
injections, animals were anesthetized with a mixture of ketamine (10
mg/kg) and xylazine (1mg/kg) andwere kept under intravenous infusion
of propofol (1% Rapinovet, 0.05–0.25 mg  kg1  min1) throughout
the procedure with continuous monitoring of cardiac and respiratory
frequencies, blood pressure, and temperature. Animals were placed in a
custom-made stereotaxic frame, and a KDS injection micropump con-
nected to aHamilton syringe and a 26 gauge needle were used to perform
five bilateral injections of 5 l of lenti-Htt82Q at a rate of 1 l/min. The
injection sites comprised two deposits in the precommissural caudate
[anterior commissure (AC)5, AC3)] and three deposits in the com-
missural and postcommissural (AC2, AC5) putamen. Postmortem
analysis was performed 16–18 months later.
Immunofluorescence. For histological processing, animals were killed
with an overdose of sodium pentobarbital. Animals were either perfused
transcardially with 4% paraformaldehyde (PFA) or their brains were
postfixed for 24 h in 4%PFA. Brains were cryoprotected by incubation in
a 30% sucrose solution. Coronal brain sections (mice, 30 m; monkey,
40m)were cut on a freezingmicrotome, collected serially, and stored at
20°C until additional analysis. Antigen retrieval protocols were used
for STAT3 and 4G8 staining. For STAT3 immunofluorescence, slices
were permeabilized with 100% methanol at20°C for 20 min. For 4G8
staining, slices were pretreated in 70% formic acid for 5 min. Sections
were then blocked with 4.5% normal goat serum (Sigma) and incubated
2818 • J. Neurosci., February 11, 2015 • 35(6):2817–2829 Ben Haim et al. • STAT3, A Universal Trigger of Astrocyte Reactivity
with primary antibodies directed against the following proteins: 4G8
(1:500, mouse; Signet Covance), EM48 (1:200, mouse; Millipore Biosci-
ence Research Reagents), GFAP–Cy3 (1:1000, mouse; Invitrogen), IBA1
(1:1000, rabbit; Wako), S100 (1:500, mouse; Invitrogen), STAT3
(STAT3, 1:200, rabbit; Cell Signaling Technology), and vimentin (1:
1000, chicken; Abcam). Anti-STAT3 antibody was diluted in Signal
Boost antibody diluent (Cell Signaling Technology). Brain sections were
incubated for 36 h with STAT3 antibody and overnight at 4°C for all
other antibodies. After rinsing, brain slices were incubated for 1–2 h at
room temperature with fluorescent secondary Alexa Fluor-conjugated
antibodies (Invitrogen). Slices were stained with DAPI (1:2000; Sigma),
mounted with FluorSave reagent (Calbiochem), and analyzed by either
epifluorescence (DM6000; Leica) or confocal microscopy (LSM 510 by
Zeiss; and TCS SPE or SP8 by Leica).
Immunohistochemistry. Brain slices were pretreated in 0.3% H2O2,
blocked in 4.5% NGS (Sigma), and incubated overnight at 4°C with
primary antibodies directed against DARPP32 (1:1000, rabbit; Santa
Cruz Biotechnology) or EM48 (1:200). After rinsing, brain slices were
incubated with biotinylated secondary antibodies (Vector Laboratories)
for 1 h at room temperature. Finally, they were incubated with the Vec-
tastain Elite ABC Kit (Vector Laboratories) and revealed with the DAB
kit (Vector Laboratories).
Cytochrome c oxidase histochemistry. Brain slices were incubated in 0.1
MPB, 4% sucrose, 0.05%DAB (Sigma), and 0.03% cytochrome c (Sigma)
for 6 h at room temperature.
qRT-PCR.Mice were killed with an overdose of sodiumpentobarbital.
Mouse brains were rapidly collected and sliced into 1-mm-thick coronal
sections with a brainmatrix. TheGFP-positive (GFP) area on each slice
was dissected with 1-mm-diameter punches (Ted Pella) under a fluores-
cence macroscope (MacroFluo; Leica). Punches were stored in RNA
Later (Sigma) until additional processing. Total RNA was isolated from
striatal punches with TRIzol (Invitrogen), and cDNA was synthesized
from 0.2 g of RNA with the VILO kit (Invitrogen) and diluted at 0.3
ng/l. The Platinum SYBR Green qPCR SuperMix UDG (Invitrogen)
was used to perform qRT-PCR. Three housekeeping genes were tested,
and the peptidylprolyl isomerase A (cyclophilin A) gene was selected as
the best normalizing gene, because it showed the minimal, nonsignifi-
cant, variation between groups. The abundance of each transcript of
interest was then normalized to the abundance of cyclophilin A with the
Ct method. The efficiency of qRT-PCR were between 85 and 110% for
each set of primers. Distilled water and RT-negative reactions were used
as negative controls. The sequences of oligonucleotides used for qRT-
PCR are as follows: aif1 (iba1), forward, CCAGCCTAAGACAAC-
CAGCGTC and reverse, GCTGTATTTGGGATCATCGAGGAA; ccl2,
forward, ACCAGCACCAGCCAACTCT and reverse, AGGCCCA-
GAAGCATGACA; cyclophilin A, forward, ATGGCAAATGCTGGAC-
CAAA and reverse, GCCTTCTTTCACCTTCCCAAA; gfap, forward,
ACGACTATCGCCGCCAACT and reverse, GCCGCTCTAGGGACT
CGTTC; itgam (CD11b), forward, GGGAGAATGCTGCGAAGA and re-
verse, GCTGGCTTAGATGCGATGG; socs3, forward, CGAGAAGAT
TCCGCTGGTACTGA and reverse, TGATCCAGGAACTCCCGAATG;
and vimentin, forward, TCGAGGTGGAGCGGGACAAC and reverse,
TGCAGGGTGCTTTCGGCTTC.
Western blotting.Mice were killed with an overdose of sodium pento-
barbital, and their brains were rapidly collected and sliced into 1-mm-
thick coronal sections with a brain matrix. The striatum or the dorsal
hippocampus were dissected out. Samples were then homogenized with
a glass homogenizer in 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, and 1%
SDS, with protease (Roche) and phosphatase (Sigma) inhibitor cocktails.
Protein concentrationwas determined by the BCAmethod. Protein sam-
ples were diluted in NuPAGE LDS sample buffer with NuPAGE Sample
Reducing agent (Life Technologies), boiled for 5min, loaded on a 4–12%
Bis-Tris gel, submitted to SDS-PAGE, and transferred to a nitrocellulose
membrane, with an iBlot transfer device (Life Technologies). Mem-
branes were blotted overnight at 4°C with antibodies against GAPDH
(1:4000, mouse; Abcam) or IB (1:500, mouse; Cell Signaling Technol-
ogy) diluted in Tris-buffered saline with 0.1% Tween 20 and 5% BSA.
After rinsing, secondary antibodies coupled to horseradish peroxidase
were incubated with the membrane for 1 h (for IB, 1:500, Cell Signal-
ing Technology; and for GAPDH, 1:5000, Vector Laboratories). Anti-
body binding was detected by a Fusion FX7 camera system (Thermo
Fisher Scientific) after incubationwith the enhanced chemiluminescence
Clarity substrate (Bio-Rad). Band intensity for IBweremeasured with
NIH Image J (http://imagej.nih.gov/ij/) and normalized to GAPDH.
Positive controls for NF-B pathway activation were included. They
were prepared from HeLa cells treated with TNF (Cell Signaling
Technology).
Quantification of immunostainings. Immunofluorescent staining was
quantified from stacked confocal images (18 steps; Z-step, 1 m, maxi-
mum intensity stack) acquired with the 40 objective on three slices per
mouse and three fields on each slice. The GFAP area was measured on
each 40 Z-stack image with the threshold function of NIH Image J.
GFAP and IBA1 areas were divided by the area of the image and
expressed as a percentage. The average number of GFAP cells express-
ing STAT3 in the nucleus (nSTAT3/GFAP cells) was quantified on
these images. In lenti-GFP-injected mice, we also quantified the average
number of GFP infected astrocytes coexpressing STAT3 (GFP/
STAT3 cells), GFAP (GFP/GFAP cells), or S100 (GFP/S100
cells). Finally, astrocyte soma was manually segmented, and the corre-
sponding mean gray value for STAT3 staining was measured with NIH
Image J. We then determined the number of cells with a mean gray value
for STAT3 over a fixed threshold for each experiment. These cells were
considered as cells expressing high levels of STAT3. Unfortunately, the
presence of autofluorescent puncta in the subiculummade it impossible
to quantify reliably the intensity of STAT3 staining in 3xTg-ADmice and
WT controls. Microscope settings and NIH Image J thresholds were
identical for all images and mice, within each experiment. Immunohis-
tochemical stainings were quantified on bright-field images, acquired
with the 2.5 (COX and DARPP32 stainings) or 10 (EM48 staining)
objectives, on five to eight serial sections per mice. The lesion was de-
tected by a loss of DARPP32 and COX staining and was manually seg-
mentedwithNIH Image J on each slice. The lesion volumewas calculated
with the Cavalieri method (Damiano et al., 2013). EM48 aggregates
were automatically detected on each imagewith the threshold function of
the Morphostrider analysis software (Explora Nova), as described previ-
ously (Francelle et al., 2014). From these measurements, the average size
and the total number of aggregates were calculated.
Statistical analysis. Results are expressed as mean  SEM. Statistical
analysis was performed with Statview software. We used Student’s t test
to compare two experimental groups and a Student’s paired t test for
left–right comparisons. The fraction of cells expressing high levels of
STAT3 was normalized by the arcsine transformation, before applying a
Student’s t test. The results of qRT-PCR were analyzed using two-way
(Htt length and treatment) ANOVA test and Scheffe´ post hoc test. The
significance level was set at p 0.05.
Results
Astrocyte reactivity is observed in vulnerable brain regions in
AD and HDmouse models
Reactive astrocytes overexpressing GFAP were found around
4G8 amyloid depositions in both the APP/PS1dE9 and the
3xTg-AD transgenic mousemodels of AD, consistent with previ-
ous findings (Oddo et al., 2003; Ruan et al., 2009). In particular,
astrocytes overexpressed GFAP and displayed hypertrophic pro-
cesses in the stratum lacunosum moleculare and the dentate
gyrus of 8-month-old APP/PS1d9 mice (Figs. 1A, 2A,B). We
quantified this phenomenon by counting the number of pixels
that were positive for GFAP staining on confocal images of the
hippocampus. The GFAP area was four times larger in APP/
PS1d9mice than inWTmice (p 0.0010, df 5, Student’s t test;
Fig. 1B). Astrocytes in APP/PS1dE9 mice also strongly expressed
vimentin (Fig. 2B). The APP/PS1dE9mouse is a quickly evolving
model of AD, with substantial deposits of amyloid at 6months of
age (Jankowsky et al., 2004). Thus, we analyzed astrocyte reactiv-
ity in 3xTg-AD mice, a more progressive model of AD. We ob-
served astrocyte reactivity around amyloid depositions primarily
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in the subicular region of the hippocam-
pus, in female 3xTg-AD mice at 12
months of age (Figs. 1C, 3A,B). In this
region, theGFAP areawas 13-fold larger
in 3xTg-AD mice than in age-matched
controls (p  0.0001, df  6, Student’s t
test; Fig. 1D). Furthermore, astrocytes
displayed a reactive morphology with en-
larged soma and processes and overex-
pressed vimentin, which was nearly
undetectable in WT mice (Fig. 3B).
We also characterized astrocyte reac-
tivity inmousemodels of HD.We studied
two HD transgenic mouse models, N171-
82Q mice (Schilling et al., 1999) and
Hdh140 knock-in HD mice (Menalled et
al., 2003). Although these models recapit-
ulate the typical features of HD, we found
that they displayed undetectable or very
late astrocyte reactivity in the striatum
and cortex, similar to what has been
described in other mouse models (Tong
et al., 2014). Thus, we focused on a
lentiviral-based model of HD that has
been used extensively (Ruiz and De´glon,
2012). This model reproduces both neu-
ronal death and strong astrocyte reactivity
in the striatum, as observed in HD pa-
tients (Faideau et al., 2010). C57BL/6mice
were injected in the left striatum with a
lentiviral vector encoding normal Htt
with 18 glutamines (lenti-Htt18Q) and in
the right striatum with a lentiviral vector
encoding mutant Htt (mHtt) with 82 glu-
tamines (lenti-Htt82Q). Mice were studied
6weeks later.As describedpreviously (Faid-
eau et al., 2010; Francelle et al., 2014), over-
expression of Htt82Q in neurons led to
the formation of intraneuronal EM48
aggregates of mHtt (Fig. 1E). In the
lenti-Htt82Q-injected striatum, astro-
cytes strongly upregulated both GFAP
and vimentin relative to the contralateral
striatum injected with lenti-Htt18Q (Figs.
1E, 4A). The GFAP area within the in-
jected area was six times larger in the
Htt82Q side than in the Htt18Q side
(p  0.0098, df  5, Student’s paired t
test; Fig. 1F).
The JAK/STAT3 pathway is activated in
reactive astrocytes in AD and HD
mouse models
Wenext evaluatedwhether astrocyte reac-
tivity observed in these models was associated with activation of
the JAK/STAT3 pathway. The phosphorylated form of STAT3
(pSTAT3) was undetectable by immunofluorescence or Western
blotting in these progressive models of ND. After activation,
pSTAT3 translocates to the nucleus in which it induces the tran-
scription of a set of target genes, including the Stat3 gene itself
(Campbell et al., 2014). Thus, we considered STAT3 nuclear lo-
calization and increased immunoreactivity as indexes of JAK/
STAT3 pathway activation, as reported previously (Escartin et al.,
2006; Tyzack et al., 2014). This also enabled us to identify cell
types displaying an active JAK/STAT3 pathway. To validate this
surrogate marker of JAK/STAT3 pathway activation, we used cil-
iary neurotrophic factor (CNTF), a well known activator of this
pathway (Bonni et al., 1993) in astrocytes (Escartin et al., 2006).
Besides increasing STAT3 phosphorylation, CNTF overexpression
in the mouse striatum increased STAT3 levels in the nucleus of re-
activeastrocytes (datanot shown). Interestingly,STAT3stainingwas
observed predominantly in astrocytes in all models of ND. In
Figure 1. Mouse models of AD and HD display astrocyte reactivity in vulnerable regions of the brain. A–C, Images of brain
sections frommousemodels of AD showing double staining for amyloid plaques (4G8, green) and astrocytes (GFAP, red). A, GFAP
is strongly expressed inhippocampal astrocytes of 8-month-oldAPP/PS1dE9mice aroundamyloiddepositions (arrowheads) in the
stratum lacunosum moleculare and the dentate gyrus. B, Quantification of the GFAP area in the hippocampus of APP/PS1dE9
and WT mice. C, In the subiculum, 3xTg-AD mice display amyloid depositions that are surrounded by GFAP reactive astrocytes
(arrowheads). D, Quantification of the GFAP area in the subiculum of 12-month-old 3xTg-ADmice and age-matchedWTmice.
E, Mice injected with lenti-Htt82Q in the striatum display EM48 aggregates of mHtt (green). Expression of the mHtt in striatal
neurons leads to astrocyte reactivity (arrowheads) as shownby increasedGFAPandvimentin staining (red).F, Quantificationof the
GFAP area in the lenti-Htt82Q-injected striatum relative to the control striatum injectedwith lenti-Htt18Q. n 3–6 per group.
**p 0.01, ***p 0.001. Scale bars: A and C, left, 100m; right, 20m; E, left, 200m; right, 20m.
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8-month-old APP/PS1dE9mice, there was an accumulation of
STAT3 in the nucleus of GFAP and vimentin reactive as-
trocytes, whereas in age-matched WT mice, STAT3 was ex-
pressed at the basal level throughout the astrocyte cytoplasm (Fig.
2A,B). The number of GFAP astrocytes expressing STAT3 in
the nucleus (nSTAT3/GFAP cells) was higher in APP/PS1dE9
mice than in age-matched WT mice (p  0.0235, df  5, Stu-
dent’s t test; Fig. 2C). We alsomeasured STAT3 immunoreactivity
in astrocyte cell bodies. The percentage of cells with high STAT3
expression was more than threefold higher in APP/PS1dE9 mice
than inWTmice, reflecting STAT3 activation in this mouse model
of AD (p 0.0226, df 5, Student’s t test; Fig. 2D).
In the subiculum of 12-month-old female 3xTg-ADmice, there
wasalsoa strong increase inSTAT3 immunoreactivity in thenucleus
of reactive astrocytes overexpressing GFAP and vimentin (Fig.
3A,B). The number of astrocytes coexpressingGFAP and STAT3 in
the nucleus was 	10-fold higher in 3xTg-AD mice than in age-
matchedWTmice (p 0.0001, df 6, Student’s t test; Fig. 3C).
We then investigated whether the JAK/STAT3 pathway was
also activated in the mouse model of HD. STAT3 staining was
strongly upregulated in reactive astrocytes
found in the lenti-Htt82Q-injected stria-
tum (Fig. 4A). Indeed, there were four
times more nSTAT3/GFAP astro-
cytes in the Htt82Q striatum than in the
Htt18Q striatum (p 0.0004, df 5, Stu-
dent’s paired t test; Fig. 4B). Cells express-
ing high levels of STAT3 were also more
abundant in the Htt82Q striatum than in
the Htt18Q striatum (p  0.0060, df  5,
Student’s paired t test; Fig. 4C). We sought
to evaluate whether the JAK/STAT3 path-
way was also activated in reactive astro-
cytes in other species. We took advantage
of the fact that lentiviral vectors can be
used in several animal species, including
nonhuman primates. Injection of lenti-
Htt82Q in the macaque putamen leads to
the formation of mHtt aggregates, neuro-
nal death, and motor symptoms (Palfi et
al., 2007). We found that the injection of
lenti-Htt82Q into the macaque putamen
induced the formation of EM48 aggre-
gates of mHtt and led to strong astrocyte
reactivity (Fig. 5). There was a prominent
accumulation of STAT3 in the nucleus of
GFAP reactive astrocytes. In contrast, at
a distance from the injection area, resting
astrocytes of the same animal expressed
nearlyundetectable levelsofbothGFAPand
STAT3 (Fig. 5).
These results suggest that the JAK/
STAT3 pathway is a common signaling
cascade for astrocyte reactivity in several
models of ND, which involve different
pathological mechanisms, brain regions,
and animal species.
The NF-B pathway is not activated in
3xTg-ADmice and in the lentiviral-
based model of HD
Other pathways, such as NF-B, have been
associated with astrocyte reactivity (Kang
andHe´bert, 2011). Therefore, we usedWestern blotting tomeasure
the abundance of IB, themaster inhibitor of theNF-Bpathway,
which is degraded during pathway activation (Hayden and Ghosh,
2008).
We performed this experiment with 3xTg-ADmice and lenti-
Htt82Q-injectedmice, because astrocyte reactivity was the stron-
gest in these models. In 3xTg-AD mice, the abundance of IB
normalized to GAPDH was similar to that in WT mice (p 
0.4037, df  8, Student’s t test; Fig. 6A), whereas the positive
control of cells treated with the cytokine TNF displayed the
expected decrease in IB levels (Fig. 6A,B). Similarly, the abun-
dance of IB normalized to GAPDH was not different between
the Htt18Q striatum and the Htt82Q striatum (p 0.8062, df
5, Student’s paired t test; Fig. 6B).
The JAK/STAT3 pathway is responsible for astrocyte
reactivity in AD and HD models
To establish that the JAK/STAT3 pathway was responsible for
astrocyte reactivity, we inhibited this pathway by overexpressing
Figure2. TheJAK/STAT3pathway isactivated inreactiveastrocytes inAPP/PS1dE9mice.A,B, Imagesofbrainsections from8-month-
oldAPP/PS1dE9mice showingdouble staining for STAT3 (green)and reactiveastrocytemarkers (A, GFAP;B, vimentin).APP/PS1dE9mice
display reactive astrocytes that overexpress GFAP, vimentin, and STAT3 around amyloid plaques (arrowhead) in the hippocampus. STAT3
accumulates inthenucleusofreactiveastrocytes(seeenlargement).C,ThenumberofGFAPastrocytescoexpressingSTAT3inthenucleus
(nSTAT3/GFAPcells) issignificantlyhigher inAPP/PS1dE9micethaninWTmice.D,Thepercentageofcellsshowingstrongstainingfor
STAT3 is higher in APP/PS1dE9mice than inWTmice.n 3–4per group. *p 0.05. Scale bars: 20m; enlargements, 5m.
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its endogenous inhibitor SOCS3 through
selective lentiviral gene transfer in astro-
cytes. SOCS3 blocks STAT association
with JAK2 (Kershaw et al., 2013) and pre-
vents its phosphorylation, operating a
negative feedback on the JAK/STAT3
pathway (Starr et al., 1997).
We usedMokola-pseudotyped lentiviral
vectors that selectively target astrocytes
(Colin et al., 2009; Figs. 7F, 8G)We did not
detect transgene expression in other brain
cell types, such as IBA1 microglia (Fig.
9A), NeuN neurons, NG2 oligodendro-
cyte progenitors, or MBP myelinating
oligodendrocytes (datanot shown). Inaddi-
tion, we checked that infection of astrocytes
with a control lentiviral vector (lenti-GFP)
did not lead to their activation in the stria-
tum of WT mice or in the subiculum of
3xTg-AD mice. In both models, GFAP ex-
pression was similar between lenti-GFP
controls and non-injected mice (data not
shown).
We first tested whether SOCS3 overex-
pression in astrocytes was able to inhibit
the JAK/STAT3pathway.WeusedCNTF to
strongly induce STAT3 phosphorylation,
and we found that coinjection with lenti-
SOCS3 significantly reduced pSTAT3 lev-
els by Western blot (data not shown). We
detected SOCS3 overexpression by qRT-
PCR after lenti-SOCS3 injection (100-fold increase; Fig. 8I), but
we were not able to show SOCS3 expression by immunohisto-
chemistry because of the lack of specific antibodies. Therefore,
for each experiment, we coinjected lenti-GFP with lenti-SOCS3
to visualize infected cells and their morphology. Indeed, we
found that injection of two lentiviral vectors leads to a large ma-
jority of infected astrocytes coexpressing the two transgenes
(88.7 2%). Controlmice were injected with lenti-GFP alone, at
the same total virus load.
Figure 4. The JAK/STAT3 pathway is activated in reactive astrocytes in the mouse model of HD. A, Images of brain sections
showing double staining for GFAP (red) and STAT3 (green) onmouse brain sections, 6 weeks after the infection of striatal neurons
with lenti-Htt18Q or lenti-Htt82Q. Astrocytes in the Htt82Q striatum are hypertrophic and express higher levels of STAT3 in their
nucleus relative to resting astrocytes in theHtt18Q striatum.B, C, The number of nSTAT3/GFAP cells (B) and the percentage of
cells displaying strong staining for STAT3 (C) are significantly higher in the Htt82Q striatum than in the Htt18Q striatum. n 6.
**p 0.01, ***p 0.001. Scale bars: 20m; enlargements, 5m.
Figure 3. The JAK/STAT3 pathway is activated in reactive astrocytes in 3xTg-AD mice. A, B, Images of brain sections from the subiculum of 12-month-old 3xTg-AD mice. STAT3 (green)
accumulates in the nucleus of reactive astrocytes labeled with GFAP (A, red) or vimentin (B, red), especially around amyloid plaques (arrowheads). C, The number of nSTAT3/GFAP cells is
significantly higher in 3xTg-AD mice than in age-matched WT controls. n 3–5 per group. ***p 0.001. Scale bars: 20m; enlargements, 5m.
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We injected lenti-SOCS3 plus lenti-GFP or lenti-GFP alone
into the subiculum of 7- to 8-month-old 3xTg-AD mice, and we
analyzed the mice 4.5 months later. The subiculum was chosen
because it is the region displaying the most prominent accumu-
lation of amyloid plaques and astrocyte reactivity at this age
(Oddo et al., 2003; Fig. 1C). In 3xTg-AD mice, SOCS3 strongly
decreased STAT3 expression in astrocytes (Fig. 7A). The number
of GFP astrocytes showing STAT3 immunoreactivity in the nu-
cleus was significantly lower inmice coinfected with lenti-SOCS3
than in those infected with lenti-GFP alone (p 0.0375, df 6,
Student’s t test; Fig. 7B). SOCS3 overexpression visibly reduced
GFAP expression in the subiculum (Fig. 7C). GFAP expression
was 73% lower in the SOCS3 group than in the GFP controls,
although this difference was not statistically significant (p 
0.0827, df 6, Student’s t test; Fig. 7D). There were significantly
fewer GFP astrocytes coexpressing GFAP in the SOCS3 group
than in the control (94%, p  0.0149, df  6, Student’s t test;
Fig. 7E). GFP expression in infected astrocytes allowed us to vi-
sualize their morphology in both groups. Astrocytes in the subic-
ulum of 3xTg-ADmice displayed a morphology characteristic of
reactive astrocytes with enlarged soma and large GFAP primary
processes (Fig. 7A,C,F). In contrast, SOCS3-infected astrocytes
displayed complex ramifications composed of thin cytoplasmic
processes organized radially around the soma (Fig. 7A,C,F), typ-
ical of resting astrocytes of the mouse brain (Wilhelmsson et al.,
2006). We also performed immunostaining for S100, a ubiqui-
tous marker of astrocytes, to verify that SOCS3 did not globally
impair protein expression in astrocytes. The number of GFP/
S100 astrocytes was similar between 3xTg-AD mice injected
with lenti-SOCS3 or lenti-GFP (Fig. 7F,G).
We performed the same experiment with the lentiviral-based
model ofHD.C57BL/6micewere injectedwith lenti-Htt82Q and
lenti-GFP in the left striatum and with lenti-Htt82Q, lenti-
SOCS3, and lenti-GFP in the right striatum at the same total virus
load. Again, SOCS3 efficiently prevented the activation of the
JAK/STAT3 pathway in astrocytes (Fig. 8A). The number of in-
fected cells coexpressing STAT3 was 87% lower in the striatum
injected with lenti-SOCS3 than in the control striatum (p 
0.0072, df  3, Student’s paired t test; Fig. 8B). In addition, the
percentage of cells highly fluorescent for STAT3 was strongly
reduced by SOCS3 (p  0.0118, df  3, Student’s paired t test;
Fig. 8C). SOCS3-expressing astrocytes displayed a bushy mor-
phology with thin cytoplasmic processes and numerous ramifi-
cations, whereas reactive astrocytes in the control striatum
showed enlarged and tortuous primary processes (Fig. 8A,D,G).
Inhibition of the JAK/STAT3 pathway by SOCS3 prevented the
increase of GFAP expression in the lenti-Htt82Q-injected area
(Fig. 8D). The GFAP area was 86% smaller in the striatum
injected with lenti-SOCS3 than in the control striatum (p 
0.0035, df  3, Student’s paired t test; Fig. 8E). In addition, the
number of GFP/GFAP cells was significantly decreased by
SOCS3 (p 0.0036, df 3, Student’s paired t test, Fig. 8F). On
the contrary, the number of GFP/S100 astrocytes was not
altered by SOCS3 (Fig. 8G,H).
Activation of the JAK/STAT3 pathway results in the transcrip-
tional activation of many genes, including gfap and vimentin.
Therefore, we studied themRNA abundance of reactive astrocyte
markers to characterize further the effect of SOCS3 expression in
astrocytes. We only used the lentiviral-based HDmodel, because
Figure 5. The JAK/STAT3 pathway is activated in reactive astrocytes in the primate model of HD. A, Images of brain sections frommacaques injected with lenti-Htt82Q in the putamen showing
triple staining for STAT3 (green), GFAP (red), and EM48 (magenta). Seventeen months after infection with lenti-Htt82Q in the putamen, EM48 aggregates of mHtt are observed, as well as
prominent astrocyte reactivity. The immunoreactivity for STAT3 ismuch stronger in GFAP reactive astrocytes than in resting astrocytes found outside the injected area in the same animal. Images
are representative of all three macaques. Scale bars: 40m; enlargement, 10m.
Figure6. TheNF-Bpathway isnotactivated in3xTg-ADmiceand the lentiviral-basedmodelof
HD.Westernblot for IBandGAPDH in3xTg-ADmice (3xTg) or their age-matchedWTcontrols (A)
ormiceinjectedintheleftstriatumwithlenti-Htt18Q(18Q)andintherightstriatumwithlenti-Htt82Q
(82Q;B). IB expression is similar between 3xTg-AD andWTmice and between the left and right
striatum of mice injected with lenti-Htt. The abundance of IB is lower in HeLa cells treated with
TNF (positive control,) than in untreated cells (negative control,).n4–6mice per group.
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the infected area in the subiculum of
3xTg-AD mice was too small to be dis-
sected out for qRT-PCR analysis. We
studied the effects of lenti-SOCS3 onmice
injected with lenti-Htt18Q or lenti-
Htt82Q compared with the control vector
lenti-GFP by performing a two-way (Htt
length and treatment) ANOVA. gfap
mRNAwas inducedmore than twofold by
lenti-Htt82Q (Fig. 8J), consistent with
immunofluorescence results. Expression
of SOCS3 in astrocytes normalized the ex-
pression of gfap to levels comparable with
controls (p  0.0254 for Htt length 
treatment effect, df 1, two-way ANOVA;
Fig. 8J ). A similar pattern was observed
with vimentin mRNA (p  0.0018 for
Htt length  treatment effect, df  1,
two-way ANOVA; Fig. 8K ). Impor-
tantly, SOCS3 overexpression in mice
injected with the control lentiviral vec-
tor lenti-Htt18Q did not change gfap or
vimentin expression, showing that
SOCS3 has no effect in resting astro-
cytes. These results suggest that inhibi-
tion of the JAK/STAT3 pathway in
reactive astrocytes restores a resting-like
status to astrocytes.
Preventing astrocyte reactivity
reduces neuroinflammation
We then evaluated how the inhibition
of astrocyte reactivity affected other
pathological features (neuroinflamma-
tion, protein aggregation, and neuronal
death).
We first studied the expression of
IBA1, a marker of microglia that is up-
regulated during microglial activation
attributable to both transcriptional regu-
lation and morphological changes (Sieber
et al., 2013). The IBA1 area was 38%
smaller in the striatum injected with lenti-
SOCS3 than in the control striatum (p
0.0397, df 5, Student’s paired t test; Fig.
9A,B). A similar effect was observed in the
subiculumof 3xTg-ADmice injectedwith
lenti-SOCS3, although it did not reach
significance (44%, p  0.1800, df  5,
Student’s t test; data not shown). We also
studied the neuroinflammatory response
at the transcriptional level. The expression
of the microglial marker aif1 (iba1) was
increased 2.3-fold byHtt82Q and reduced
by SOCS3 (p  0.0048 for Htt length 
treatment effect, df 1, two-way ANOVA;
Fig. 9C). Similarly, the marker for reactive
microglia itgam (CD11b) and the chemo-
kine ccl2 were increased 2.3- and 4.1-fold,
respectively, byHtt82Qandreduced tocon-
trol levels by SOCS3 (p  0.0165 and p 
0.0001, respectively, for Htt length treat-
ment effect, df 1, two-way ANOVA; Fig.
Figure 7. The JAK/STAT3 pathway is responsible for astrocyte reactivity in 3xTg-AD mice. A, Images of double staining
for GFP (green) and STAT3 (red) in 7- to 8-month-old 3xTg-ADmice injected in the subiculumwith lenti-GFP or lenti-SOCS3
plus lenti-GFP (same total virus load). STAT3 expression becomes undetectable in astrocytes infected with lenti-SOCS3. B,
The number of GFP astrocytes coexpressing STAT3 in the nucleus (GFP/nSTAT3 cells) is significantly lower in the
SOCS3 group than in the GFP control group. C, Images of GFP (green) and GFAP (red) staining in brain sections from 3xTg-AD
mice injected with lenti-GFP or lenti-SOCS3 plus lenti-GFP in the subiculum. Lenti-SOCS3 injection strongly reduces GFAP
expression in the injected area (delimited by white dots) in 3xTg-ADmice. Note that infected astrocytes in the SOCS3 group
have a bushy morphology typical of resting astrocytes, whereas cells in the GFP group are hypertrophic with enlarged
primary processes. D, Quantification of the GFAP area in 3xTg-AD mice injected with lenti-SOCS3 plus lenti-GFP or
lenti-GFP alone. E, The number of GFP astrocytes coexpressing GFAP is significantly lower in the SOCS3 group than in the
GFP control group. F, Immunofluorescent labeling for the astrocyte marker S100. G, Quantification of the number of
infected astrocytes coexpressing S100 (GFP/S100 cells) shows that its expression is not altered by SOCS3. n 3–5
per group. *p 0.05. Scale bars: A and F, 20 m; C, left, 500 m; right, 20 m. Infected astrocytes in both groups are
identified by their expression of GFP.
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Figure8. The JAK/STAT3pathway is responsible for astrocyte reactivity in the lentiviral-basedmousemodel of HD.A, Immunofluorescent staining of GFP (green) and STAT3 (red) inmice injected
in the left striatum with lenti-Htt82Q plus lenti-GFP and the right striatum with lenti-Htt82Q plus lenti-SOCS3 plus lenti-GFP. STAT3 expression becomes undetectable in astrocytes infected with
lenti-SOCS3.B,C, Thenumber ofGFP/nSTAT3astrocytes (B) and thepercentageof cells showing strong staining for STAT3 (C) is significantly lower in the right striatum injectedwith lenti-SOCS3
than in the control striatum. D, SOCS3 expression strongly reduces GFAP expression (red) in the injected area (GFP, green). Infected astrocytes in the SOCS3 group display thin processes and
complex ramifications, unlike hypertrophic reactive astrocytes in the control group. E, Quantification confirms that the GFAP area is significantly smaller in the striatum injectedwith lenti-SOCS3
than in the control striatum.F, Thenumber of GFP astrocytes coexpressingGFAP is significantly lower in the striatumexpressing SOCS3 than in the control striatum.G, Immunofluorescent staining
for the astrocyte marker S100 (red). H, The number of GFP/S100 cells is not different between the two groups. I–K, qRT-PCR analysis on mice injected in the striatum (Figure legend continues.)
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9D,E). These results suggest that inhibition of astrocyte reactivity
reduces the neuroinflammatory response.
Preventing astrocyte reactivity modulates HD pathology
Finally, we evaluated the effects of SOCS3 on neuronal death and
mHtt aggregation. Htt82Q induced a lesion detected by a loss of
DARPP32 staining and COX activity. SOCS3 did not change the size
of the lesion asmeasuredwith these twomarkers (p 0.2088 and p
0.1508, respectively, df 10, Student’s paired t test; Fig. 10). However,
SOCS3 significantly increased the number of EM48mHtt aggregates
(p0.0409,df10,Student’spaired t test;Fig.10).Theaverage sizeof
EM48 aggregates was not different between the GFP and SOCS3
groups (GFP, 10.20  0.30 m2; SOCS3, 10.60  0.48 m2, p 
0.3638).
Overall, our results identify the JAK/STAT3 pathway as a pivotal
and universal signaling cascade for astrocyte reactivity in various
models of ND. Inhibition of the JAK/STAT3 pathway in reactive
astrocytes influences several disease outcomes in the context of HD.
Discussion
Activation of the JAK/STAT3 pathway is a universal feature of
astrocyte reactivity
The JAK/STAT3 pathway is known to trigger astrocyte reactivity
in models of acute injury (Kang and He´bert, 2011). We aimed to
decipher the role of the JAK/STAT3 pathway in astrocyte reactiv-
ity during progressive pathological conditions, such as ND.
Active pSTAT3 could not be detected by immunohistochem-
istry; therefore, we used increased STAT3 expression and nuclear
localization as alternative indicators of pathway activation, as de-
scribed previously by us and others (Escartin et al., 2006; Tyzack et
al., 2014). The absence of pSTAT3 immunoreactivitywas not attrib-
utable to a technical problem because we were able to detect it with
the positive control CNTF. Instead, it may be attributable to the
models of ND themselves, which are progressive and may involve
low, transient, or asynchronous phosphorylation of STAT3. We
show that the JAK/STAT3pathway is activated in reactive astrocytes
inmousemodelsofbothADandHDand inaprimatemodelofHD.
Importantly, the etiology of the two ND studied here is very
different and involves particular vulnerable brain regions. Thus,
activation of the JAK/STAT3 pathway appears to be a universal
feature of astrocyte reactivity, observed in multiple brain disor-
ders, both acute and progressive. Both resting and reactive astro-
cytes are now considered as highly heterogeneous cells in terms of
their morphological or functional features (Anderson et al.,
2014). However, our results suggest that the molecular cascades
triggering reactivity are in fact highly conserved between disease
states, species, and brain regions.
In addition to the threemousemodels studied here, we exam-
ined astrocyte reactivity in two transgenic mouse models of HD.
Both N171-82Q and Hdh140 mice display behavioral abnormal-
ities and striatal atrophy. However, we did not observe substan-
tial astrocyte reactivity in end-stage N171-82Qmice or before 17
months of age in Hdh140 mice. Interestingly, the JAK/STAT3
pathway was also found activated in the few reactive astrocytes of
the old Hdh140 mouse. This limited astrocyte reactivity in HD
transgenic mice is consistent with the literature (Tong et al.,
4
(Figure legend continued.) with lenti-Htt18Q plus lenti-GFP, lenti-Htt18Q plus lenti-SOCS3 plus
lenti-GFP, lenti-Htt82Q plus lenti-GFP, or lenti-Htt82Q plus lenti-SOCS3 plus lenti-GFP (same
total virus load). I, Socs3 mRNA is overexpressed	100 times after lenti-SOCS3 injection. The
expression of gfap (J) and vimentin (K) is induced by lenti-Htt82Q and is restored to levels
observed in the Htt18Q controls by the expression of SOCS3. Note that lenti-SOCS3 has no effect
in resting astrocytes. n 4–11 per group. *p 0.05, **p 0.01, ***p 0.001. Scale bars:
A and G, 20m; D, 500M; enlargement, 20m.
Figure 9. Preventing astrocyte reactivity reduces microglial activation. A, Immunofluorescent staining of GFP (green) and IBA1 (red) in mice injected in the left striatumwith lenti-Htt82Q plus
lenti-GFP and the right striatumwith lenti-Htt82Qplus lenti-SOCS3plus lenti-GFP.B, Quantification shows that the IBA1 area is significantly smaller in the striatum injectedwith lenti-SOCS3 than
in the control striatum. C–E, qRT-PCR analysis on mice injected in the striatum with lenti-Htt18Q plus lenti-GFP, lenti-Htt18Q plus lenti-SOCS3 plus lenti-GFP, lenti-Htt82Q plus lenti-GFP, or
lenti-Htt82Q plus lenti-SOCS3 plus lenti-GFP (same total virus load). The expression of aif1 (iba1; C), itgam (CD11b;D), and ccl2 (E) is induced by lenti-Htt82Q and is reduced by SOCS3. n 4–11 per
group. *p 0.05, **p 0.01, ***p 0.001, #p 0.05 versus Htt18Q plus GFP and Htt18Q plus SOCS3. Scale bar, 20m.
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2014) but differs greatly from what is observed in HD patients
(Faideau et al., 2010). This discrepancy may be related to the
absence of massive neuronal death in HD transgenic models.
Thus, we focused on the lentiviral-basedmodel ofHD that repro-
duces neuronal death in the striatum, along with strong astrocyte
reactivity.
Astrocyte reactivity in NDmodels is mediated by the
JAK/STAT3 pathway
By immunohistological and biochemical techniques, it was
shown that the JAK/STAT3 pathway is activated in reactive astro-
cytes in several models of acute injury (Justicia et al., 2000; Xia et
al., 2002) and inALS (Shibata et al., 2010). Experiments involving
pharmacological inhibitors of the JAK/STAT3 pathway later sug-
gested that this pathway was needed for astrocyte reactivity, in-
cluding in theMPTPmodel of PD (Sriram et al., 2004). However,
the JAK/STAT3 pathway is active in all brain cells; therefore, it is
possible that such inhibitors affect other cell types besides astro-
cytes. More recently, genetic approaches have been developed to
knock out the expression of STAT3 specifically in astrocytes with
the Cre–LoxP system. STAT3 conditional knock-out strongly re-
duces astrocyte reactivity after acute injuries (Okada et al., 2006;
Herrmann et al., 2008; Tyzack et al., 2014). However, the use of a
non-inducible Cre recombinase expressed under a nestin or gfap
promoter may trigger side effects, because these promoters are
active during embryonic development (Alvarez-Buylla et al.,
2001). In contrast, our strategy based on SOCS3 overexpression
by lentiviral gene transfer results in an efficient inhibition of the
JAK/STAT3 pathway specifically in astrocytes of the adult brain.
Indeed, SOCS3was able to prevent the ac-
cumulation of STAT3 in the nucleus of
reactive astrocytes in ND models and to
blunt the strong phosphorylation of
STAT3 induced by CNTF. This selective
approach allowed us to demonstrate
that the JAK/STAT3 pathway is respon-
sible for astrocyte reactivity in twomod-
els of ND.
In agreement with a pivotal role of the
JAK/STAT3 pathway for astrocyte reac-
tivity, we observed no evidence for an ac-
tivation of the NF-B pathway in these
models. This pathway is associated with
astrocyte reactivity in acute disorders,
such as spinal cord injury (Kang and
He´bert, 2011). In AD and HD, the NF-B
pathway is altered in neurons (Chiba et
al., 2009; Khoshnan and Patterson, 2011)
but is activated in the peripheral immune
cells of HD patients (Tra¨ger et al., 2014)
and in astrocytes inmousemodels of both
diseases (Hsiao et al., 2013; Medeiros and
LaFerla, 2013). However, the specific re-
quirement of this pathway for the estab-
lishment of reactivity in astrocytes has not
been tested in these NDs. The NF-B
pathway is activated mainly in microglial
cells in the SODG93A mouse model of ALS
(Frakes et al., 2014). Indeed, inhibition of
the NF-B pathway in astrocytes reduced
their reactivity very moderately and only
transiently (Crosio et al., 2011). In both
studies, inhibition of the NF-B pathway
in astrocytes did not influence disease outcomes, further suggest-
ing that this pathway does not play a major role in reactive astro-
cytes during ND.
There are multiple levels of crosstalk between the NF-B and
the JAK/STAT3 pathways (Fan et al., 2013). It is possible that the
NF-B pathway secondarily activates the JAK/STAT3 pathway or
that STAT3 inhibits the NF-B pathway (Yu et al., 2002). Al-
though other signaling pathways may be active in astrocytes or in
other cell types during the disease, our experiments based on the
specific inhibition by SOCS3 in astrocytes show that the JAK/
STAT3 pathway is ultimately responsible for triggering astrocyte
reactivity in these ND.
Viral vectors are versatile tools; therefore, our approach based
on a lentiviral vector encoding an inhibitor of the JAK/STAT3
pathway could be easily extended to any animal model of brain
disease, including those affecting different brain regions. How-
ever, one limitation is that lentiviral vectors may transduce a
small number of cells, especially in the subiculum, preventing
qRT-PCR or biochemical analysis by Western blotting.
What are the effects of STAT3-mediated astrocyte reactivity?
The JAK/STAT3 pathway is a ubiquitous signaling pathway in-
volved in cell proliferation, survival, and differentiation (Levy
and Darnell, 2002). In adult astrocytes, activation of the JAK/
STAT3 pathway increases the expression of cytoskeletal proteins,
such as GFAP and vimentin, as observed here, but many other
genes could be induced, as shown in reactive astrocytes after isch-
emia or LPS injection in vivo (Zamanian et al., 2012). In particu-
lar, reactive astrocytes may release several signaling molecules,
Figure 10. Preventing astrocyte reactivity modulates HD pathology. Immunostaining of the striatal neuronal marker
DARPP32 and histochemistry of COX in mice injected in the left striatum with lenti-Htt82Q plus lenti-GFP and in the right
striatum with lenti-Htt82Q plus lenti-SOCS3 plus lenti-GFP. mHtt aggregates are detected by immunostaining with EM48
in the same mice, and they form nuclear inclusions (see enlargement). Quantification of the lesion size and the number of
EM48 aggregates. SOCS3 increases the number of EM48 aggregates.n 11. *p 0.05. Scale bar, 500m.
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such as cytokines or chemokines, that affect neighboring cells,
including microglial cells (Burda and Sofroniew, 2014). Indeed,
we found an increased expression of neuroinflammationmarkers
in the lenti-basedmodel ofHD, whichwas restored to basal levels
by SOCS3. This observation suggests that reactive astrocytes are
responsible for microglial activation in this model and illustrates
the complex dialog occurring between glial cells in ND.
Blunting astrocyte reactivity by SOCS3 also increased the
number of mHtt aggregates, suggesting that reactive astrocytes
participate in mHtt processing and aggregation. Because those
mHtt aggregates are found mainly in neurons, such an effect
necessarily involves neuron-to-astrocyte communication. Inter-
estingly, it was reported recently that mHtt can propagate be-
tween neurons (Pecho-Vrieseling et al., 2014), opening the
possibility that it may also be exchanged between neurons and
glial cells. More experiments are needed to decipher the molecu-
lar mechanisms responsible for the control of mHtt clearance by
reactive astrocytes.
It is still highly debated how mHtt inclusions contribute to
neuronal death: it may be toxic, protective, or without effect
(Arrasate and Finkbeiner, 2012). We show that increasing the
number of mHtt aggregates does not influence the lesion, which
is in favor of a disconnection between mHtt aggregates and neu-
ronal death. Indeed, the inclusions of mHtt measured here are
only the end products ofmHttmetabolism, and it is nowbelieved
that soluble or oligomeric mHtt are the toxic species (Leitman et
al., 2013).
We show that interfering with astrocyte reactivity influences
two important features of HD (neuroinflammation and mHtt
aggregation) but did not affect neuronal death.However, we can-
not exclude that the lentiviral-basedmodel of HD is too severe to
allow restoration by the modulation of astrocyte and microglia
reactivity or mHtt aggregation.
A similar thorough evaluation of SOCS3 effects could not be
performed in the 3xTg-AD model because the volume targeted
with lenti-SOCS3 was too small to provide a reliable quantifica-
tion of disease indexes, such as amyloid load. There are conflict-
ing reports on the role of reactive astrocytes in AD (Furman et al.,
2012; Kraft et al., 2013). It may be clarified by inhibiting the
JAK/STAT3 pathway, identified here as an instrumental cascade
to promote reactivity, and assessing the consequences on AD
outcomes.
Our study extends previous findings obtained in acutemodels
of injury and suggests that the JAK/STAT3 pathway is a universal
signaling cascade involved in virtually all pathological situations
in the brain.Manipulation of the JAK/STAT3 pathway is a prom-
ising strategy to study the functional features of reactive astro-
cyte, as well as their contribution to disease progression,
particularly in the context of ND.
References
Alvarez-Buylla A, García-Verdugo JM, Tramontin AD (2001) A unified hy-
pothesis on the lineage of neural stem cells. Nat Rev Neurosci 2:287–293.
CrossRef Medline
AndersonMA, Ao Y, SofroniewMV (2014) Heterogeneity of reactive astro-
cytes. Neurosci Lett 565:23–29. CrossRef Medline
ArrasateM, Finkbeiner S (2012) Protein aggregates inHuntington’s disease.
Exp Neurol 238:1–11. CrossRef Medline
Bjørbaek C, Elmquist JK, Frantz JD, Shoelson SE, Flier JS (1998) Identifica-
tion of SOCS-3 as a potential mediator of central leptin resistance. Mol
Cell 1:619–625. CrossRef Medline
Bonni A, Frank DA, Schindler C, GreenbergME (1993) Characterization of
a pathway for ciliary neurotrophic factor signaling to the nucleus. Science
262:1575–1579. CrossRef Medline
Burda JE, Sofroniew MV (2014) Reactive gliosis and the multicellular re-
sponse to CNS damage and disease. Neuron 81:229–248. CrossRef
Medline
Campbell IL, Erta M, Lim SL, Frausto R, May U, Rose-John S, Scheller J,
Hidalgo J (2014) Trans-signaling is a dominant mechanism for the
pathogenic actions of interleukin-6 in the brain. J Neurosci 34:2503–
2513. CrossRef Medline
Chiba T, Yamada M, Sasabe J, Terashita K, Shimoda M, Matsuoka M, Aiso S
(2009) Amyloid-beta causes memory impairment by disturbing the
JAK2/STAT3 axis in hippocampal neurons. Mol Psychiatry 14:206–222.
CrossRef Medline
Colin A, Faideau M, Dufour N, Auregan G, Hassig R, Andrieu T, Brouillet E,
Hantraye P, Bonvento G, De´glon N (2009) Engineered lentiviral vector
targeting astrocytes in vivo. Glia 57:667–679. CrossRef Medline
Crosio C, Valle C, Casciati A, Iaccarino C, Carrì MT (2011) Astroglial inhi-
bition ofNF-kappaB does not ameliorate disease onset and progression in
a mouse model for amyotrophic lateral sclerosis (ALS). PLoS One
6:e17187. CrossRef Medline
Damiano M, Diguet E, Malgorn C, D’Aurelio M, Galvan L, Petit F, Benhaim
L, Guillermier M, Houitte D, Dufour N, Hantraye P, Canals JM, Alberch
J, Delzescaux T, De´glon N, Beal MF, Brouillet E (2013) A role of mito-
chondrial complex II defects in genetic models of Huntington’s disease
expressing N-terminal fragments of mutant huntingtin. HumMol Genet
22:3869–3882. CrossRef Medline
de Almeida LP, Ross CA, Zala D, Aebischer P, De´glon N (2002) Lentiviral-
mediated delivery of mutant huntingtin in the striatum of rats induces a
selective neuropathology modulated by polyglutamine repeat size, hun-
tingtin expression levels, and protein length. J Neurosci 22:3473–3483.
Medline
Escartin C, Bonvento G (2008) Targeted activation of astrocytes: a potential
neuroprotective strategy. Mol Neurobiol 38:231–241. CrossRef Medline
Escartin C, Brouillet E, Gubellini P, Trioulier Y, Jacquard C, Smadja C, Knott
GW, Kerkerian-Le Goff L, De´glon N, Hantraye P, Bonvento G (2006)
Ciliary neurotrophic factor activates astrocytes, redistributes their gluta-
mate transporters GLAST and GLT-1 to raft microdomains, and im-
proves glutamate handling in vivo. J Neurosci 26:5978–5989. CrossRef
Medline
Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G, Dufour N,
GuillermierM, Brouillet E, Hantraye P, De´glon N, Ferrante RJ, Bonvento
G (2010) In vivo expression of polyglutamine-expanded huntingtin by
mouse striatal astrocytes impairs glutamate transport: a correlation with
Huntington’s disease subjects. Hum Mol Genet 19:3053–3067. CrossRef
Medline
Fan Y, Mao R, Yang J (2013) NF-kappaB and STAT3 signaling pathways
collaboratively link inflammation to cancer. Protein Cell 4:176–185.
CrossRef Medline
Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L,Miranda
CJ, Ladner KJ, BevanAK, Foust KD,Godbout JP, Popovich PG,Guttridge
DC, Kaspar BK (2014) Microglia induce motor neuron death via the
classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron
81:1009–1023. CrossRef Medline
Francelle L, Galvan L, Gaillard MC, Guillermier M, Houitte D, Bonvento G,
Petit F, Jan C, Dufour N, Hantraye P, Elalouf JM, de Chaldee M, Deglon
N, Brouillet E (2014) Loss of the thyroid hormone binding protein
Crym renders striatal neurons more vulnerable to mutant huntingtin in
Huntington’s disease. HumMol Genet. Advance online publication. Re-
trieved January 8, 2015. doi:10.1093/hmg/ddu571. CrossRef Medline
Furman JL, Sama DM, Gant JC, Beckett TL, Murphy MP, Bachstetter AD,
Van Eldik LJ, Norris CM (2012) Targeting astrocytes ameliorates neu-
rologic changes in a mouse model of Alzheimer’s disease. J Neurosci
32:16129–16140. CrossRef Medline
HambyME, SofroniewMV (2010) Reactive astrocytes as therapeutic targets
for CNS disorders. Neurotherapeutics 7:494–506. CrossRef Medline
HaydenMS,Ghosh S (2008) Shared principles inNF-kappaB signaling. Cell
132:344–362. CrossRef Medline
Herrmann JE, Imura T, Song B,Qi J, AoY,NguyenTK, Korsak RA, TakedaK,
Akira S, SofroniewMV (2008) STAT3 is a critical regulator of astroglio-
sis and scar formation after spinal cord injury. J Neurosci 28:7231–7243.
CrossRef Medline
Hottinger AF, Azzouz M, De´glon N, Aebischer P, Zurn AD (2000) Com-
plete and long-term rescue of lesioned adult motoneurons by lentiviral-
mediated expression of glial cell line-derived neurotrophic factor in the
facial nucleus. J Neurosci 20:5587–5593. Medline
2828 • J. Neurosci., February 11, 2015 • 35(6):2817–2829 Ben Haim et al. • STAT3, A Universal Trigger of Astrocyte Reactivity
Hsiao HY, Chen YC, Chen HM, Tu PH, Chern Y (2013) A critical role of
astrocyte-mediated nuclear factor-kappaB-dependent inflammation in
Huntington’s disease. HumMol Genet 22:1826–1842. CrossRef Medline
Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D (1989) Relationship of
microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neu-
roimmunol 24:173–182. CrossRef Medline
Jankowsky JL, FadaleDJ, Anderson J, XuGM,Gonzales V, JenkinsNA, Cope-
land NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR
(2004) Mutant presenilins specifically elevate the levels of the 42 residue
beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific
gamma secretase. HumMol Genet 13:159–170. CrossRef Medline
Justicia C, Gabriel C, Planas AM (2000) Activation of the JAK/STAT path-
way following transient focal cerebral ischemia: signaling through Jak1
and Stat3 in astrocytes. Glia 30:253–270. CrossRef Medline
Kang W, He´bert JM (2011) Signaling pathways in reactive astrocytes, a ge-
netic perspective. Mol Neurobiol 43:147–154. CrossRef Medline
KershawNJ,Murphy JM, LiauNP, Varghese LN, Laktyushin A,Whitlock EL,
Lucet IS, Nicola NA, Babon JJ (2013) SOCS3 binds specific receptor-
JAK complexes to control cytokine signaling by direct kinase inhibition.
Nat Struct Mol Biol 20:469–476. CrossRef Medline
Khoshnan A, Patterson PH (2011) The role of IkappaB kinase complex in
the neurobiology of Huntington’s disease. Neurobiol Dis 43:305–311.
CrossRef Medline
Kraft AW, Hu X, Yoon H, Yan P, Xiao Q, Wang Y, Gil SC, Brown J, Wil-
helmsson U, Restivo JL, Cirrito JR, Holtzman DM, Kim J, Pekny M, Lee
JM (2013) Attenuating astrocyte activation accelerates plaque patho-
genesis in APP/PS1 mice. FASEB J 27:187–198. CrossRef Medline
Leitman J, Ulrich Hartl F, Lederkremer GZ (2013) Soluble forms of polyQ-
expanded huntingtin rather than large aggregates cause endoplasmic re-
ticulum stress. Nat Commun 4:2753. CrossRef Medline
Levy DE, Darnell JE Jr (2002) Stats: transcriptional control and biological
impact. Nat Rev Mol Cell Biol 3:651–662. CrossRef Medline
MedeirosR,LaFerlaFM (2013) Astrocytes: conductorsof theAlzheimerdisease
neuroinflammatory symphony. ExpNeurol 239:133–138. CrossRefMedline
Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF (2003) Time
course of early motor and neuropathological anomalies in a knock-in
mouse model of Huntington’s disease with 140 CAG repeats. J Comp
Neurol 465:11–26. CrossRef Medline
Naldini L, Blo¨mer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM,
Trono D (1996) In vivo gene delivery and stable transduction of nondi-
viding cells by a lentiviral vector. Science 272:263–267. CrossRef Medline
O’Callaghan JP, Kelly KA, VanGilder RL, Sofroniew MV, Miller DB (2014)
Early activation of STAT3 regulates reactive astrogliosis induced by di-
verse forms of neurotoxicity. PLoS One 9:e102003. CrossRef Medline
Oddo S, CaccamoA, Shepherd JD,MurphyMP, Golde TE, Kayed R,Mether-
ate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic
model of Alzheimer’s disease with plaques and tangles: intracellular Abeta
and synaptic dysfunction. Neuron 39:409–421. CrossRef Medline
Okada S, Nakamura M, Katoh H, Miyao T, Shimazaki T, Ishii K, Yamane J,
Yoshimura A, Iwamoto Y, Toyama Y, Okano H (2006) Conditional ab-
lation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after
spinal cord injury. Nat Med 12:829–834. CrossRef Medline
Palfi S, Brouillet E, Jarraya B, Bloch J, JanC, ShinM,Conde´ F, Li XJ, Aebischer
P, Hantraye P, De´glonN (2007) Expression ofmutated huntingtin frag-
ment in the putamen is sufficient to produce abnormal movement in
non-human primates. Mol Ther 15:1444–1451. CrossRef Medline
Pecho-Vrieseling E, Rieker C, Fuchs S, Bleckmann D, Esposito MS, Botta P,
Goldstein C, Bernhard M, Galimberti I, Mu¨ller M, Lu¨thi A, Arber S,
Bouwmeester T, van der PuttenH, Di Giorgio FP (2014) Transneuronal
propagation of mutant huntingtin contributes to non-cell autonomous
pathology in neurons. Nat Neurosci 17:1064–1072. CrossRef Medline
Probst A, Ulrich J, Heitz PU (1982) Senile dementia of Alzheimer type:
astroglial reaction to extracellular neurofibrillary tangles in the hip-
pocampus. An immunocytochemical and electron-microscopic study.
Acta Neuropathol 57:75–79. CrossRef Medline
Ruan L, Kang Z, Pei G, Le Y (2009) Amyloid deposition and inflammation
in APPswe/PS1dE9 mouse model of Alzheimer’s disease. Curr Alzheimer
Res 6:531–540. CrossRef Medline
Ruiz M, De´glon N (2012) Viral-mediated overexpression of mutant hun-
tingtin to model HD in various species. Neurobiol Dis 48:202–211.
CrossRef Medline
Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt
HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross
CA, Borchelt DR (1999) Intranuclear inclusions and neuritic aggregates
in transgenic mice expressing a mutant N-terminal fragment of hunting-
tin. HumMol Genet 8:397–407. CrossRef Medline
Shibata N, Kakita A, Takahashi H, Ihara Y, Nobukuni K, Fujimura H, Sakoda
S, Sasaki S, Iwata M, Morikawa S, Hirano A, Kobayashi M (2009) Acti-
vation of signal transducer and activator of transcription-3 in the spinal
cord of sporadic amyotrophic lateral sclerosis patients. Neurodegener Dis
6:118–126. CrossRef Medline
Shibata N, Yamamoto T, Hiroi A, Omi Y, Kato Y, Kobayashi M (2010)
Activation of STAT3 and inhibitory effects of pioglitazone on STAT3
activity in amousemodel of SOD1-mutated amyotrophic lateral sclerosis.
Neuropathology 30:353–360. CrossRef Medline
Sieber MW, Jaenisch N, Brehm M, Guenther M, Linnartz-Gerlach B, Neu-
mann H, Witte OW, Frahm C (2013) Attenuated inflammatory re-
sponse in triggering receptor expressed on myeloid cells 2 (TREM2)
knock-out mice following stroke. PLoS One 8:e52982. CrossRef Medline
Sofroniew MV, Vinters HV (2010) Astrocytes: biology and pathology. Acta
Neuropathol 119:7–35. CrossRef Medline
Sriram K, Benkovic SA, Hebert MA, Miller DB, O’Callaghan JP (2004) In-
duction of gp130-related cytokines and activation of JAK2/STAT3 path-
way in astrocytes precedes up-regulation of glial fibrillary acidic protein in
the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinemodel of neurodegen-
eration: key signaling pathway for astrogliosis in vivo? J Biol Chem 279:
19936–19947. CrossRef Medline
Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ,
Alexander WS, Metcalf D, Nicola NA, Hilton DJ (1997) A family of
cytokine-inducible inhibitors of signalling. Nature 387:917–921. CrossRef
Medline
TongX, AoY, FaasGC,Nwaobi SE, Xu J,HausteinMD,AndersonMA,Mody
I, Olsen ML, Sofroniew MV, Khakh BS (2014) Astrocyte Kir4.1 ion
channel deficits contribute to neuronal dysfunction in Huntington’s dis-
ease model mice. Nat Neurosci 17:694–703. CrossRef Medline
Tra¨ger U, Andre R, Lahiri N, Magnusson-Lind A, Weiss A, Grueninger S,
McKinnon C, Sirinathsinghji E, Kahlon S, Pfister EL, Moser R, Hum-
merich H, Antoniou M, Bates GP, Luthi-Carter R, Lowdell MW,
Bjo¨rkqvist M, Ostroff GR, Aronin N, Tabrizi SJ (2014) HTT-lowering
reverses Huntington’s disease immune dysfunction caused by NFkappaB
pathway dysregulation. Brain 137:819–833. CrossRef Medline
Tyzack GE, Sitnikov S, Barson D, Adams-Carr KL, Lau NK, Kwok JC, Zhao C,
Franklin RJ, Karadottir RT, Fawcett JW, Lakatos A (2014) Astrocyte re-
sponse to motor neuron injury promotes structural synaptic plasticity via
STAT3-regulatedTSP-1expression.NatCommun5:4294.CrossRefMedline
Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr
(1985) Neuropathological classification of Huntington’s disease. J Neu-
ropathol Exp Neurol 44:559–577. CrossRef Medline
Wilhelmsson U, Bushong EA, Price DL, Smarr BL, Phung V, Terada M,
EllismanMH, PeknyM (2006) Redefining the concept of reactive astro-
cytes as cells that remain within their unique domains upon reaction to
injury. Proc Natl Acad Sci U S A 103:17513–17518. CrossRef Medline
Xia XG, Hofmann HD, Deller T, Kirsch M (2002) Induction of STAT3 sig-
naling in activated astrocytes and sprouting septal neurons following en-
torhinal cortex lesion in adult rats. Mol Cell Neurosci 21:379–392.
CrossRef Medline
Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ (2003) Mutant huntingtin
causes context-dependent neurodegeneration in mice with Huntington’s
disease. J Neurosci 23:2193–2202. Medline
Yu Z, Zhang W, Kone BC (2002) Signal transducers and activators of tran-
scription 3 (STAT3) inhibits transcription of the inducible nitric oxide
synthase gene by interacting with nuclear factor kappaB. Biochem J 367:
97–105. CrossRef Medline
Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA (2012)
Genomic analysis of reactive astrogliosis. J Neurosci 32:6391–6410.
CrossRef Medline
Ben Haim et al. • STAT3, A Universal Trigger of Astrocyte Reactivity J. Neurosci., February 11, 2015 • 35(6):2817–2829 • 2829
